Coherus Oncology, Inc.
Coherus Oncology, Inc.
- Market cap
- $57.15M
Your view on CHRS
Overview
What the company does, where it operates, and who runs it.
About Coherus Oncology, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Dennis M. Lanfear
- Headquarters
- 333 Twin Dolphin Drive, Redwood City, CA, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Dennis M. Lanfear
- Headquarters
- 333 Twin Dolphin Drive, Redwood City, CA, US
Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States.
The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin 27.
It also develops CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, Anti-ILT4 monoclonal antibody for solid tumors.
In addition, the company offers GSK4381562, an antibody targeting CD112R to treat tumor cells; YUSIMRY, a biosimilar to Humira for inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, such as rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis; and CIMERLI, a Lucentis biosimilar to treat neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization.
It has a collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc. and Surface and Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited.
The company was formerly known as Coherus BioSciences, Inc. and changed its name to Coherus Oncology, Inc. in May 2025. The company was incorporated in 2010 and is based in Redwood City, California.
Stock Data
Price chart, volume, and trading data.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Coherus Oncology, Inc.. Starting points for Coherus Oncology, Inc.: EPS -$0.87, beta 1.03 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Coherus Oncology, Inc.. Trailing twelve-month EPS for Coherus Oncology, Inc. stands at -$0.87. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Coherus Oncology, Inc.. Coherus Oncology, Inc. has reported as a listed company since 2014. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| CAICaris Life Sciences, Inc. | Healthcare | NASDAQ | $5.0B | ||
| CAIHFChia Tai Enterprises International Limited | Healthcare | OTC | $217.4M | ||
| CALACalithera Biosciences, Inc. | Healthcare | OTC | $974 | ||
| CALCCalciMedica, Inc. | Healthcare | NASDAQ | $4.0M | ||
| CAMPCAMP4 Therapeutics Corporation | Healthcare | NASDAQ | $237.8M | ||
| CAMRFCamurus AB (publ) | Healthcare | OTC | $3.5B | ||
| CANFCan-Fite BioPharma Ltd. | Healthcare | AMEX | $1.9M | ||
| CAPRCapricor Therapeutics, Inc. | Healthcare | NASDAQ | $439.6M | ||
| CARMCarisma Therapeutics, Inc. | Healthcare | NASDAQ | $2.4M | ||
| CASBFCanSino Biologics Inc. | Healthcare | OTC | $1.3B | ||
| CASIFCASI Pharmaceuticals, Inc. | Healthcare | PNK | — | ||
| CBDGTHC Farmaceuticals, Inc. | Healthcare | OTC | $797,790 | ||
Institutional Ownership
Which funds and firms own the stock.
About this section
Which institutions hold Coherus Oncology, Inc., and how their positions are changing. At a $57.1M market value, institutional positions materially move Coherus Oncology, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
About this section
Buying and selling by Coherus Oncology, Inc. executives and directors. Shares of Coherus Oncology, Inc. have traded between $0.71 and $2.43 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for Coherus Oncology, Inc.. Coverage tracks Coherus Oncology, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Coherus Oncology, Inc.